Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype.
Jang GB, Kim JY, Cho SD, Park KS, Jung JY, Lee HY, Hong IS, Nam JS. · 2015
Read Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. by Jang GB, Kim JY, Cho SD, Park KS, Jung JY, Lee HY, Hong IS, Nam JS. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5378883.txt.
Introduction
Gyu-Beom Jang and co-authors blocked a growth signal to curb breast cancer spread, in Scientific Reports in 2015. A small set of stem-like cells in a tumor can seed its return and its spread to far organs. In breast cancer stem cells, the Wnt signal path, which runs through the protein beta-catenin, fires far harder than in the bulk of the tumor. That heat marks the stem set and tracks a poor outlook.
The team asked if jamming the path would strand the stem cells. With the path blocked, the cells lost their self-renewal and their drive to move, acts that feed growth and spread. Stem-linked genes fell in step. Tests in dishes and in mice agreed: tumors grew less and spread less. The path, they argue, is a true lever on the stem set, and a drug target worth chase.
Catalog record
| CREATOR | Jang GB, Kim JY, Cho SD, Park KS, Jung JY, Lee HY, Hong IS, Nam JS. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype By Gyu-Beom Jang, Ji-Young Kim, Sung-Dae Cho, Ki-Soo Park, Ji-Youn Jung, Hwa-Yong Lee, In-Sun Hong, Jeong-Seok Nam Published in: Scientific Reports DOI: 10.1038/srep12465 ABSTRACT Abstract The identification of cancer stem cells (CSCs) represents an important milestone in the understanding of chemodrug resistance and cancer recurrence. More specifically, some studies have suggested that potential metastasis-initiating cells (MICs) might be present within small CSC populations. The targeting and eradication of these cells represents a potential strategy for significantly improving clinical outcomes. A number of studies have suggested that dysregulation of Wnt/β-catenin signaling occurs in human breast cancer. Consistent with these findings, our previous data have shown that the relative level of Wnt/β-catenin signaling activity in breast cancer stem cells (BCSCs) is significantly higher than that in bulk cancer cells. These results suggest that BCSCs could be sensitive to therapeutic approaches targeting Wnt/β-catenin signaling pathway. In this context, abnormal Wnt/β-catenin signaling activity may be an important clinical feature of breast cancer and a predictor of poor survival. We therefore hypothesized that Wnt/β-catenin signaling might regulate self-renewal and CSC migration, thereby enabling metastasis and systemic tumor dissemination in breast cancer. Here, we investigated the effects of inhibiting Wnt/β-catenin signaling on cancer cell migratory potential by examining the expression of CSC-related genes, and we examined how this pathway links metastatic potential with tumor formation in vitro and in vivo. Metastasis/invasion and systemic tumor dissemination from primary tumors are the most detrimental events that occur during cancer progression. It has been hypothesized that a small subpopulation of cancer cells, namely metastasis-initiating cells (MICs), might exist, although these cells have not yet been prospectively identified. Multiple lines of recent evidence strongly suggest that MICs might exist within small subpopulations of cancer stem cells (CSCs) inside of tumors. First, CSCs possess a high tumor-initiating capacity, which is an essential characteristic that enables the formation of new tumors (secondary and tertiary foci) beyond the point at which the original tumor formed1,2. Second, CSCs express epithelial-mesenchymal transition (EMT) markers3, which are associated with the ability of tumor cells to migrate into other tissues or organs. More specifically, some studies have suggested that potential MICs might be present within small CSC populations, for example, CD44+/CD24low breast cancer cells with stem cell-like properties have been proposed to exhibit enhanced tumorigenic and metastatic properties in tumor xenograft models4,5. Interestingly, accumulating evidence indicates a critical role of Wnt/β-catenin signaling in the functioning of CSCs6,7,8. For example, mammary stem cells with high levels of Wnt/β-catenin signaling have a much greater tumorigenic potential than their counterparts with low levels of this type of signaling9. Therefore, the findings of these studies suggest that Wnt/β-catenin signaling in MICs may be a promising therapeutic target in breast cancer. Wnt proteins are a family of secreted, glycosylated, and palmitoylated peptides that mediate a wide variety of processes during embryogenesis by regulating stem cell division, migration, and integrity of the stem cell niche10,11. Furthermore, aberrant activation of the Wnt/β-catenin signaling pathway has been suggested to play an important regulatory role during the development of several types of human cancers. For example, activating mutations in Wnt/β-catenin signaling components, including β-catenin, Axin, and APC, have been reported in colorectal cancer (CRC) patients12 and are also major causes of malignant transformation13. Until recently, it was generally assumed that dysregulation of the Wnt/β-catenin signaling pathway rarely, if ever, occurred in breast tumors, in contrast with that in CRC14. However, subsequent studies have suggested that in breast cancer, dysregulation of this signaling pathway may be caused by disruption of its negative regulators. Consistent with this notion, expression of the extracellular inhibitor of Wnt/β-catenin signaling, secreted frizzled-related protein 1 (also known as SFRP1), which competes with the Wnt signaling receptor FZD for ligand binding, is significantly down-regulated in many breast cancers and is associated with poor survival and a poor therapeutic response15,16,17. Recently, upregulation of the Wnt/β-catenin signaling pathway has also been shown to lead to increased tumor metastasis from the primary tumor18,19,20. In the present study, we therefore aimed to explore a limiting factor in metastatic development using a mouse model of breast cancer in which cancer spontaneously metastasizes to the lungs21. We hypothesized that Wnt/β-catenin signaling might regulate the self-renewal and migration of CSCs, thereby enabling metastasis and systemic tumor dissemination in breast cancer. Here, we investigated the effects of inhibition of Wnt/β-catenin signaling on cancer cell migration potential by examining the expression of CSC-related genes, and we assessed the manner by which this pathway links metastatic potential with tumor formation. Finally, we showed that inhibition of the Wnt/β-catenin signaling pathway preferentially reduced the metastatic potential by altering CSC activity in a mouse model of breast cancer. Collectively, these data suggest that Wnt/β-catenin signaling is a potential therapeutic target for breast cancer treatment. RESULTS Wnt/β-catenin signaling activity is enhanced in malignant breast cancer tissues compared with their normal counterparts Recently, accumulating evidence has demonstrated a critical role of Wnt/β-catenin signaling in cancer stemness and malignant behavior6,22,23. Consistent with previous studies, which have shown elevated Wnt/β-catenin signaling activity in different cancer cell models, our immunocytochemical results revealed that Wnt/β-catenin signaling was activated to a greater extent in cancerous tissues compared with that in non-cancerous tissues (Fig. 1A). To further investigate the connection between breast tumorigenesis and Wnt/β-catenin signaling, we evaluated breast cancer datasets available through the Oncomine dataset repository (www.oncomine.org). Filtering specifically for breast cancer datasets that included prognostic stages (categories) based on the size of the tumor and extent of metastasis, we found correlations between cancer stage and the expression of negative (GSK3β) or positive (TCF4) regulators of Wnt/β-catenin signaling (Fig. 1B). These data indicate that Wnt/β-catenin signaling might be associated with poor prognosis and could contribute to the metastatic potential of breast cancer. [Figure: Comparison of Wnt/β-catenin signaling-related genes in malignant breast cancer tissues and their normal counterparts.Cancerous and non-cancerous breast tissues (kindly provided by Dr. Lee at the National Cancer Center, Korea) were stained with antibodies against Wnt1. Wnt1 was expressed to a greater extent in the cancerous tissues than in the non-cancerous tissues. DAPI staining was performed to label the nuclei within each field (A). A significant correlation between poor prognosis and the expression of a negative (GSK3β) or positive (TCF4) regulator of Wnt/β-catenin signaling was observed in the human breast cancer datasets assessed, which were obtained through the Oncomine dataset repository (www.oncomine.org) (B). The results are presented as the mean ± SD, as determined from more than three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.] Blockade of Wnt/β-catenin signaling suppresses the growth and phenotypic characteristics of BCSCs We used two well-characterized breast cancer cell lines with different metastatic properties to examine the regulatory effects of Wnt/β-catenin signaling on the malignant properties of breast cancer cells24, including 67NR cells, which form a primary tumor readily, but tumor cells do not intravasate from the primary tumor, and 4T1 cells, which are fully metastatic and form macroscopic metastatic nodules on the lung surfaces from primary tumors, as illustrated in Fig. 2A. First, to examine the regulatory role of Wnt/β-catenin signaling in BCSCs, we analyzed the expression of the transcription factor TCF-4, a critical regulator of Wnt/β-catenin signaling25, in